• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus

tetano

Editor, Senior Moderator
J Med Virol


. 2022 Jan 22.
doi: 10.1002/jmv.27614. Online ahead of print.
Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus


Fabiola Justina Fumero León[SUP] 1 [/SUP], Lucas Lima da Silva[SUP] 2 [/SUP], Alanna Calheiros Santos[SUP] 2 [/SUP], Vanessa Duarte da Costa[SUP] 2 [/SUP], Juliana Custódio Miguel[SUP] 2 [/SUP], Julia Trece Marques[SUP] 2 [/SUP], Giselle Prado do Nascimento[SUP] 2 [/SUP], Elisangela Ferreira da Silva[SUP] 2 [/SUP], Lia Laura Lewis-Ximenez[SUP] 2 [/SUP], Livia Melo Villar[SUP] 2 [/SUP], Vanessa Salete de Paula[SUP] 1 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can generate a systemic inflammatory response, characterized by a cytokine storm and associated with an exaggerated release of pro-inflammatory cytokines, including tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and IL-17, all of which can affect the liver. Here, we aimed to evaluate the cytokine profiles of patients suffering from coronavirus disease (COVID)-19 and/or hepatitis. We subjected 87 patients to serology and/or polymerase chain reaction analysis for hepatitis C virus. They were also tested for TNF-α, IL-6, and IL-17 using commercial immunoassay kits. The test results of the COVID-19/hepatitis C patients (n = 8) were compared with that of the negative controls (n = 28), hepatitis C patients (n = 29), and COVID-19 patients (n = 22). All COVID-19 patients (mono- and co-infected) expressed high levels of cytokines. The COVID-19/hepatitis patients exhibited higher levels of IL-6 (6.33 ± 3.9 pg/mL), and IL-17 (102.23 ± 2.7 pg/mL); however, TNF-α values were lower (68.08 ± 15.88 pg/mL), as compared to that of the hepatitis patients (p < 0.001), and lower than that of the COVID-19 patients and exceptionally for TNF-α (p < 0.05). These data highlight the importance of monitoring patients with hepatitis and COVID-19. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; IL-17; IL-6; TNF-α.; cytokines; hepatitis.
 
Back
Top Bottom